Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Minoxidil · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Topical 5% minoxidil foam formulation used twice daily |
| vehicle of 5% Minoxidl topical foam | PLACEBO_COMPARATOR | vehicel foam in twice daily application in temple and vertex region |
| 5% Minoxidil topical foam | ACTIVE_COMPARATOR | 5% Minoxidil topical in twice daily application in temple and vertex region |
| Name | Type | Description |
|---|---|---|
| minoxidil | DRUG | Topical 5% minoxidil foam, BID, for sixteen weeks |
| vehicle of 5% Minoxidil topical foam | DRUG | 1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase |
Inclusion Criteria: * presence of androgenetic alopecia with vertex pattern IIIv, IV, or V on the Norwood Hamilton Scale * Male sex, age 15 to 49, good health * Willingness to have a dot tattoo placed in the target area of the scalp during the study * Willingness to maintain normal shampooing habit...
Minoxidil is a small molecule treatment being developed for androgenetic alopecia, a common form of hair loss. It is being studied in male patients with this condition. The clinical program includes trials evaluating minoxidil foam versus placebo foam for androgenetic alopecia and male pattern hair loss.
Minoxidil targets KCNJ11 and ABCC9, which are potassium channel proteins. It acts as an opener of these channels. This mechanism is distinct from hormonal approaches to hair loss and is the basis for its investigation in androgenetic alopecia.
Johnson & Johnson, ticker JNJ, is the developer of Minoxidil for androgenetic alopecia. The company is conducting clinical trials of the drug in this indication.
Minoxidil is in Phase 3 development for androgenetic alopecia. It is an investigational therapy and has not been approved for this indication. The Phase 3 trial has been completed, and no active trials are currently listed.
Minoxidil has been studied in two clinical trials: NCT01319370, a completed Phase 2 trial of minoxidil foam versus placebo foam in Germany with 70 male participants, and NCT00151515, a completed Phase 3 trial of 5 percent minoxidil foam in the United States with 352 male participants.